معرفی
Professor Paul Freemont is a leading academic in structural and synthetic biology at Imperial College London, serving as Head of the Section of Structural and Synthetic Biology within the Department of Infectious Disease. His research focuses on integrating structural biology tools to study human disease mechanisms and developing synthetic biology foundational technologies such as biofoundries, automation, and cell-free systems for applications in biosensing, metabolic engineering, and synthetic cells.
Freemont holds a PhD from the University of Aberdeen (1984) and BSc from Heriot-Watt University (1980). He has held leadership positions including Co-Director of the UK National Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE), Director of the London Biofoundry, and Co-Founder of the Global Biofoundry Alliance. His work spans academic, industrial, and policy dimensions, with contributions to the World Economic Forum, UK government advisory groups, and international consortia like the Engineering Biology Research Consortium.
His research interests are reflected in affiliations with numerous centers including the Centre for Structural Biology, Institute for Molecular Science and Engineering, and UK Dementia Research Institute. Over 300 scientific publications and prestigious fellowships (Royal Society of Biology, Royal Society of Chemistry) underscore his impact. Recent work emphasizes pandemic preparedness through standardized testing protocols and biofoundry-driven biotechnology innovation.
Freemont advocates strongly for commercialization of engineering biology through Imperial spin-outs like Solena Materials and SynBioVen. His lab's tools include the One-Pot PURE cell-free system, SNAILS biosensors, and Streptomyces-based synthetic biology platforms. Active in biosecurity and policy, he chairs global working groups on engineering biology standards and metrics.
